Monday March 29, 2021
Destiny Pharma to Join Equity Development Webinar
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel Primary endpoint achieved with >99% […]
Monday March 29, 2021
29 Mar 2021 – Destiny Pharma Phase 2b results – Analyst and Investor webcast and con...
The link to join the Phase 2b results webcast and conference call for analysts and investors, Monday 29th March at 1100 BST, is given below:- Phase 2b results webcast and […]
Monday March 29, 2021
Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent […]
Tuesday March 16, 2021
16 Mar 2021 – Notice of Full Year Results and Clinical Trial Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Clinical Trial Update Brighton, United Kingdom – 16th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage […]
Monday March 15, 2021
15 Mar 2021 – Destiny Pharma Announces Agreement with NIAID
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection Brighton, United Kingdom, 15 March 2021 […]
Wednesday March 10, 2021